-80.3%
OKLO vs MRNA
+945.0%
-1,025.3%
-81.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.8% | +13.1% | -18.9% | -6.8% |
| 7D | -18.4% | +20.6% | -39.1% | -19.7% |
| 30D | -38.5% | +27.1% | -65.7% | -39.9% |
| 3M | -48.9% | +353.4% | -402.3% | -58.6% |
| 6M | -67.8% | +446.3% | -514.0% | -76.1% |
| YTD | -69.2% | +776.2% | -845.3% | -80.9% |
| 1Y | -80.3% | +987.9% | -1,068.2% | -88.7% |
| All | -80.3% | +945.0% | -1,025.3% | -88.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling